Net Loss: Net loss was $198.1 million for the year ended December 31, 2023, as compared to $121.8 million for the year ended December 31, 2022. Part of the increase was attributable to a one-time charge for the Company’s settlement with Myeloid Therapeutics, Inc. Cash Position: As of ...
Lonza和BioWa与FivePrime Therapeutics签署授权协议,允许FivePrime使用其POTELLIGENT® CHOK1SV细胞系开发治疗抗体 新泽西州普林斯顿、瑞士巴塞尔和加州南旧金山2012年6月13日电 /美通社亚洲/ -- Five Prime Therapeutics, Inc.(简称“FivePrime”)已经与 BioWa, Inc. 和 Lonza 签署了研究和商业协议,FivePrime 将使用...
662 Portfolio 244 Exits 171 F-Prime CapitalGeneral Information Company Description Founded in 1969, F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts. The firm seeks to invest in companies operating in the healthcare, therapeutics, medtech, health information technology, ser...